Advancing Peptide-Based Vaccines Against Candida: A Comparative Perspective on Liposomal and Synthetic Formulations

The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing...

Full description

Saved in:
Bibliographic Details
Published in:Journal of fungi (Basel) Vol. 11; no. 10; p. 715
Main Author: Xin, Hong
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 02.10.2025
Subjects:
5-Methyltetrahydrofolate-homocysteine S-methyltransferase
Adjuvants
Animal models
Antibodies
Antifungal agents
antifungal immunotherapy
Antigen presentation
Antigens
Candida auris
Cobalt
CoPoP liposomes
Cytokines
Drug dosages
Drug resistance
Fructose
Fungal infections
Immunogenicity
Immunology
Licenses
Lymphocytes
Lymphocytes T
Medical prognosis
Methionine
Multidrug resistance
Pathogens
peptide vaccine
Peptides
SNAP platform
Tropical diseases
Vaccination
Vaccines
Candida auris
antifungal immunotherapy
SNAP platform
CoPoP liposomes
peptide vaccine
ISSN:2309-608X, 2309-608X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The growing threat of multidrug-resistant fungal pathogens, especially Candida auris, has underscored the need for effective antifungal vaccines. This commentary highlights recent advances in peptide-based vaccination using the SNAP (Spontaneous Nanoliposome Antigen Presentation) platform, focusing on the FM-SNAP vaccine, a bivalent liposomal formulation targeting the surface-expressed peptides fructose bisphosphate aldolase (Fba) and methionine synthase (Met6). Compared to earlier constructs such as MP12, FM-SNAP achieves superior immunogenicity and long-lasting protection at lower antigen doses. It elicits balanced Th1/Th2 cytokine responses and demonstrates durable efficacy in both immunocompetent and complement-deficient mouse models. The platform’s compatibility with clinically approved adjuvants (MPLA and QS-21), modular peptide design, and potential for multi-pathogen applications underscores its translational promise. FM-SNAP exemplifies a next-generation vaccine strategy that is both scalable and adaptable for high-risk immunocompromised populations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:2309-608X
2309-608X
DOI:10.3390/jof11100715